key: cord-0293214-2g8a78op
authors: Freilich, D.; Victory, J.; Gadomski, A.
title: Hydroxychloroquine/Chloroquine in COVID-19 With Focus on Hospitalized Patients - A Systematic Review
date: 2022-01-14
journal: nan
DOI: 10.1101/2022.01.11.22269069
sha: 79e72965db83098705eed5ea13dbc94ef8f20ec0
doc_id: 293214
cord_uid: 2g8a78op

Background In the beginning of the COVID-19 pandemic, many hospitalized patients received empiric hydroxychloroquine/chloroquine (HC/CQ). Although some retrospective-observational trials suggested potential benefit, all subsequent randomized clinical trials (RCTs) failed to show benefit and use generally ceased. Herein, we summarize key studies that clinicians advising patients on HC/CQ efficacy:safety calculus in hospitalized COVID-19 patients would want to know about in a practical one-stop-shopping source. Methods Pubmed and Google were searched on November 4, 2021. Search words included: COVID-19, hydroxychloroquine, chloroquine, in vitro, animal studies, clinical trials, and meta-analyses. Studies were assessed for import and included if considered impactful for benefit:risk assessment. Results These searches led to inclusion of 12 in vitro and animal reports; 12 retrospective-observational trials, 19 interventional clinical trials (17 RCTs, 1 single-arm, 1 controlled but unblinded), and 51 meta-analyses in hospitalized patients. Inconsistent efficacy was seen in vitro and in animal studies for coronaviruses and nil in SARS-CoV-2 animal models specifically. Most retrospective-observational studies in hospitalized COVID-19 patients found no efficacy; QT prolongation and increased adverse events and mortality were reported in some. All RCTs and almost all meta-analyses provided robust data showing no benefit in overall populations and subgroups, yet concerning safety issues in many. Conclusions HC/CQ have inconsistent anti-coronavirus efficacy in vitro and in animal models, and no convincing efficacy yet substantial safety issues in the overwhelming majority of retrospective-observational trials, RCTs, and meta-analyses in hospitalized COVID-19 patients. HC/CQ should not be prescribed for hospitalized COVID-19 patients outside of clinical trials.

The overwhelming majority of meta-analyses found no benefit for 27 hydroxychloroquine/chloroquine in COVID-19 inpatients, 28 outpatients, or for prophylaxis, and many found concerning safety 29 signals. 30 31 32 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

More than 770,000 Americans have died of COVID-19, and U.S. deaths continue at 1,000-2,000 65 daily. Thus, it is imperative that we confirm the beneficial efficacy:safety calculus of effective 66 medications (positive studies) but also the absence of beneficial efficacy:safety calculus of 67 purportedly effective medications (negative studies), so we refrain from prescribing them 68 potentially causing harm. Lessons should be learned from the successes and failures in response 69 to the pandemic. The story of the medical community's empiric prescribing of hydroxychloroquine 70 (HC) and chloroquine (CQ) despite weak a priori data and a progressively negative preclinical 71 and clinical database during the pandemic should be instructive to avoid repetition in this latter 72 phase of the pandemic. 73 HC received early pandemic attention for use in COVID-19 in part because then President Trump 74 recommended and took it for post-exposure prophylaxis. HC was frequently administered 75 empirically (peaking at a whopping 42% prevalence for hospitalized COVID-19 patients early in 76 the pandemic [1] ) and recommended in some expert reviews and guidelines (e.g., [2] ). Supportive 77 data were shaky, relying on inconsistent in vitro and animal studies mainly for other coronaviruses 78 assessing HC/CQ in hospitalized COVID-19 patientsalmost all found ineffectiveness, and many 92 found adverse safety signals (e.g., [43] [44] [45] ). 93

This review summarizes the evolved benefits:risks database for HC/CQ in the COVID-19 94 pandemic, aiming to assist clinicians in easily summarizing the evidence basis for their 95 benefits:risk assessment to their patients, some of whom (as well as other experts) continue to 96 believe in possible effectiveness of these medications in some indications (e.g., [46] ). 97 98

Pubmed and Google searches were conducted, with the latest repeated November 4, 2021. Initial 100 search words included "COVID-19", "hydroxychloroquine", and "chloroquine", found 3,123 101 publications. 102

Adding search words, "clinical trials", reduced this list to 78 publications -15 RCTs and 5 103 retrospective-observational trials in hospitalized patients, 4 RCTs in outpatients, 6 RCTs 104 evaluating prophylaxis, and 48 other studies (not evaluating HC/CQ, not trials, unable to 105 categorize). For hospitalized COVID-19 patients, the primary focus of this review, the Google 106 search, as well as findings from the other Pubmed searches below (e.g., in vitro studies), led to 107 inclusion of 4 additional studies (2 RCTs, 1 single-arm trial, and 1 prospective controlled 108 observational trial) and 7 additional retrospective-observational trials yielding 19 interventional 109 trials (17 of which were RCTs) and 12 retrospective-observational trials. Of the 17 RCTs, 5 110 published earlier in the pandemic were evaluated in detail systematically because they impacted 111 evolving FDA recommendations and guidelines more than latter RCTs which tended to be 112 confirmatory and additive to established literature (summarized but not detailed herein); all 5 113 included hard primary outcomes (i.e., mortality, ordinal scores, and viral clearance) with most 114 comparing primary outcome risk, rate, and odds ratios; standard baseline patient characteristics 115 were collected in all; 4 vs. 1 were assessed as having moderate and mild risk of bias, respectively 116 (Table S1) . 117

Adding "meta-analysis" to the Pubmed search led to 62 publications, 12 of whom were not 118 focusing on hospitalized COVID-19 patients were excluded yielding a total of 50 meta-analyses; 119 our unpublished IPD meta-analysis was added yielding a total of 51 meta-analyses in hospitalized 120 patients (3 examples were detailed). 121

The Pubmed search led to the finding of 4 outpatient RCTs; the Google search found two additional 122 studies (1 retrospective-observational study and 1 RCT) yielding a total of 6 outpatient studies. 123

The Pubmed search led to finding 6 prophylaxis studies; the Google search found an additional 3 124 studies (1 RCT, 2 observational cohort) yielding a total of 9 prophylaxis studies. 125

Adding the key words, "in vitro", to our Pubmed search, resulted in 277 publications of which 126 only 6 were in fact in vitro studies and thus included in our preclinical review. Our Google and 127 other Pubmed searches found 2 additional studies, yielding 8 in vitro studies. Adding key words, 128 "animal studies", resulted in 89 publications of which only 4 were in fact animal studies and thus 129 included in our preclinical summary; no additional studies were found with the Google or other 130

Pubmed searches. In total, 12 preclinical studies were included in this review (8 in vitro, 4 animal). 131 See Figure 1 . 132

We prioritized detailing of RCTs, larger retrospective-observational studies, and larger (especially 133 IPD) meta-analyses as these were considered 'more impactful'. Uncontrolled trials, smaller 134 retrospective-observational studies, and smaller aggregate data meta-analyses (and as noted, later 135 confirmatory RCTs) were considered 'less impactful '. 136 This systematic review was not based on a written protocol nor was it registered. inconsistently as only two of three studies found viral growth inhibition in Vero E6 cell (African 147 green monkey kidney cells) and one found no growth inhibition in a human airway epithelial model 148 [52] [53] [54] . One study found that growth inhibition by quinine exceeds that by HC or CQ in Vero 149 cells, human Caco-2 colon epithelial cells, lung A549 cells, and Calu-3 lung epithelial cells [55] . The in vitro data for SARS viruses and relative safety of these medications in malaria and 177 rheumatoid arthritis in part prompted recommendations by some expert groups and guidelines 178 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 14, 2022. RCTs early in the pandemic led to the inclusion of recommendation in some Chinese guidelines 206 to treat hospitalized COVID-19 patients with HC/CQ [11] after data from more than 100 patient 207 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 14, 2022. ; https://doi.org/10.1101/2022.01.11.22269069 doi: medRxiv preprint also showed less pulmonary complication and more rapid viral shedding and clinical improvement 208 [15]. In the Boston series in 90 patients, combined therapy was associated with a larger median 227 increase in the QT interval than HC monotherapy (23 vs. 5.5 msec, p=0.03), resulting in 13% vs. 228 3% of patients, respectively, having QTc change >/= 60 msec. The risk of QTc prolongation to 229 >/=500 msec was similar (21% vs. 19%). The authors implied a baseline QTc prolongation 230 exclusion. Ten patients (11%) discontinued medication because of adverse events (nausea, 231 hypoglycemia, and one case of delayed torsades de pointes) [16] . 232 None of these series had control arms, so the relative risk of QTc prolongation remained elusive. 233

Yet, it appeared that higher dosing and co-administration of QTc prolonging medications resulted 234 in more frequent and severe QTc prolongation. Torsades de pointes, the feared QTc prolongation 235 complication, appeared rare (occurring in only 1 of 211 patients in the series [0.5%]). An 236 accompanying JAMA editorial concluded, the studies "underscore the potential risk … of 237 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 14, 2022. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 14, 2022. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 14, 2022. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 14, 2022. ; https://doi.org/10.1101/2022.01.11.22269069 doi: medRxiv preprint HAHPS RCT comparing 85 patients treated with HC vs. azithromycin with a Bayesian analysis, 386 no convincing difference was found for the primary outcome, the 14-day ordinal score [34]; AE 387 rates, QTc prolongation were similar but the AKI rate was numerically higher with HC. In a 388 combined report of a Taiwanese small open-labeled RCT (n=34) and small retrospective study 389 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 14, 2022. ; https://doi.org/10.1101/2022.01.11.22269069 doi: medRxiv preprint A descriptive safety analysis from three of these outpatient RCTs (1 non-hospitalized mild-502 moderate disease RCT, 1 post-exposure prophylaxis RCT, and 1 pre-exposure prophylaxis RCT) 503 in 2,795 subjects found increased AE rates with HC (36-40%) vs. placebo (19%) but rare SAEs; 504 GI upset was the most common AE. Co-administration of other QT prolonging medications was 505 an exclusion in these RCTs [85] . 506

An open-label cluster study in migrants in Singapore showed higher viral clearance with HC vs. 507 vitamin C control [86] . An Indian open-labeled, controlled study in 317 exposed or presumed 508 exposed subjects showed significantly decreased infection rates with HC post-exposure 509 prophylaxis vs. SOC [87] . 510 A potential critique of some of the post-exposure prophylaxis studies has been that HC/CQ was 511 sometimes administered late after symptoms onset leading to decreased efficacyas occurs with 512 delayed neuraminidase inhibitor treatment for influenza and in some experimental SARS-CoV-2 513 mouse models [88] . Higher dosing than necessary based on predicted pharmacokinetics, leading 514 to more adverse events, has also been a critique. 515

An unpublished medRxiv aggregate date meta-analysis including five pre-and post-exposure 516

prophylaxis RCTs reported possible benefit for HC [89] . 517

In summary, HC/CQ has not been found to have significant efficacy for pre-exposure prophylaxis 518 against COVID-19 in most but not all studies and increased AEs in some, however the published 519 database is much more limited than for hospitalized patients. 520 521

The key limitation of this review is that systematic adherence to PRISMA checklist [90] 523 components was high for HC/CQ studies in hospitalized patients (the focus of this review) but 524 lower for the other studies (e.g., no risk of bias assessment in the latter). 525 526

This systematic review of preclinical in vitro and animal studies, retrospective-observational trials, 528

RCTs, and meta-analyses strongly suggests that HC/CQ are ineffective in hospitalized patients 529 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 14, 2022. ; https://doi.org/10.1101/2022.01.11.22269069 doi: medRxiv preprint with COVID-19, both in overall populations and in subpopulations, and should not be administered 530 outside of RCTs with robust informed consent about unlikely benefit and probable harm. We 531 believe that the preclinical and clinical database was never sufficient to support empiric use. 532

The published clinical trials database for HC/CQ in outpatients and post-exposure and pre-533 exposure prophylaxis also shows lack of convincing efficacy despite increased adverse events, but 534 it is more limited than for hospitalized patients, particularly for pre-exposure prophylaxis. Our 535 review was less robust for these indications. 536

Empiricism, particularly when based mainly on retrospective-observational studies rather than 537

RCTs, is fraught with danger for patients. Cognizance of the story of HC/CQ's failure during the 538 COVID-19 pandemic should lead to refraining on the part of the medical community from 539

repeating the same errors for other experimental therapeutics. Dr. Kalil's wise admonition in his 540

May 2020 JAMA viewpoint bears repeating: "The administration of any unproven drug as a 'last 541 resort' wrongly assumes that benefit will be more likely than harm" [91] . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 14, 2022. ; https://doi.org/10.1101/2022.01.11.22269069 doi: medRxiv preprint Pubmed and Google searches were used to query the published preclinical and clinical literature 820 for hydroxychloroquine and chloroquine use for treatment and prophylaxis in COVID-19 821 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 14, 2022. ; https://doi.org/10.1101/2022.01.11.22269069 doi: medRxiv preprint

Use of Hydroxychloroquine, Remdesivir, and 552 Dexamethasone Among Adults Hospitalized With COVID-19 in the United States. A 553 Retrospective Cohort Study

Interim Guidance on Management Pending Empirical 555 Evidence. From an American Thoracic Society-led International Task Force: From an 556

American Thoracic Society-led International Task Force

Hydroxychloroquine prophylaxis and treatment is 559 ineffective in macaque and hamster SARS-CoV-2 disease models

Antiviral efficacies of FDA-approved drugs against SARS

CoV-2 infection in ferrets

Hydroxychloroquine 564 and azithromycin as a treatment of COVID-19 results of an open-label non-randomized 565 clinical

No evidence of rapid antiviral clearance or clinical benefit with the 567 combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 568 infection

Request for Emergency Use Authorization For Use of Chloroquine Phosphate or 570

Hydroxychloroquine Sulfate Supplied From the Strategic National Stockpile for Treatment of 571 2019 Coronavirus Disease

Effect of hydroxychloroquine and azithromycin 574 as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update 575 with an intention-to-treat analysis and clinical outcomes

Efficacy of hydroxychloroquine in patients with COVID-19: 578 results of a randomized clinical trial

Low dose of hydroxychloroquine reduces fatality of critically ill patients with 580 COVID-19

Chinese Guidelines Related to Novel 582 Coronavirus Pneumonia

Breakthrough: Chloroquine phosphate has shown apparent efficacy in 584 treatment of COVID-19 associated pneumonia in clinical studies

Effect of High vs Low Doses of Chloroquine 587 Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory 588 Syndrome Coronavirus 2 (SARS-CoV-2) Infection

Caution Needed on the Use of Chloroquine and 591 Hydroxychloroquine for Coronavirus Disease

Assessment of Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in 596 an Intensive Care Unit

Risk of QT Interval Prolongation Associated With Use 598 of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized 599 Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)

Outcomes 602 of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19

Observational Study of Hydroxychloroquine in Hospitalized 605 Patients with Covid-19

Association of Treatment With Hydroxychloroquine 607 or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in

RETRACTED: Hydroxychloroquine or 610 chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry 611 analysis

Clinical Efficacy of hydroxychloroquine in patients 613 with covid-`9 pneumonia who require oxygen: observational comparative study using routine 614 care data

Treatment with hydroxychloroquine, azithromycin, 616 and combination in patients hospitalized with COVID-19

Safety, tolerability, and clinical outcomes of 619 hydroxychloroquine for hospitalized patients with coronavirus 2019 disease

Effect of Combination Therapy of Hydroxychloroquine 622 and Azithromycin on Mortality in Patients With COVID-19

Hydroxychloroquine in patients with mainly mild to moderate 629 coronavirus disease 2019: open label, randomised controlled trial

Effect of Hydroxychloroquine in Hospitalized Patients 631 with Covid-19. The RECOVERY Collaborative Group

Effect of Hydroxychloroquine on Clinical Status at 633 14 Days in Hospitalized Patients With COVID-19A Randomized Clinical Trial

Repurposed Antiviral Drugs for Covid-19 -636 Interim WHO Solidarity Trial Results. WHO Solidarity Trial Consortium

Hydroxychloroquine with or without 639 Azithromycin in Mild-to-Moderate Covid-19

A pragmatic randomized controlled trial reports 641 lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics

Hydroxychloroquine in the treatment of COVID-644 19: a multicenter randomized controlled study

Treating COVID-19 with hydroxychloroquine 647 (TEACH): a multicenter, double-blind randomized controlled trial in hospitalized patients

Azithromycin for Hospitalized 650 Patients with COVID-19 (HAHPS): Results of a Randomized

A multicenter, randomized, open-label, controlled trial to 653 evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult 654 patients with mild to moderate coronavirus disease 2019 (COVID-19)

An 657 open-label severe COVID-19 patients

Phase 2 randomized study on chloroquine, 661 hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of 662 SARS-CoV-2 infection. Pathogens and Global Health

Lopinavir-ritonavir and hydroxychloroquine for 664 critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive 665 Care Med

Hydroxychloroquine in mild-to-moderate coronavirus 667 disease 2019: a placebo-controlled double blind trial

Evaluation of the effects of remdesivir 673 and hydroxychloroquine on viral clearance in COVID-19: a randomized trial

Azithromycin and hydroxychloroquine in 676 hospitalised patients with confirmed COVID-19-a randomised double-blinded placebo-677 controlled trial

Mortality outcomes with hydroxychloroquine and 679 chloroquine in COVID-19 from an international collaborative meta-analysis of randomized 680 trials

Chloroquine or hydroxychloroquine for 682 prevention and treatment of COVID-19

Hydroxychloroquine or Chloroquine for the Treatment of Hospitalized 684 Patients with COVID-19. An Individual Participant Data Meta-Analysis

Causal inference in a time of coronavirus: tenofovir, tocilizumab, 687 hydroxychloroquine

Evaluation of Immunomodulators, Interferons and 691 Known in Vitro SARS-CoV Inhibitors for Inhibition of SARS-Cov Replication in BALB/c

Remdesivir and chloroquine effectively inhibit the recently 694 emerged novel coronavirus (2019-nCoV) in vitro

Hydroxychloroquine, a less toxic derivative of chloroquine, is 696 effective in inhibiting SARS-CoV-2 infection in vitro

Chloroquine is a potent inhibitor of SARS 698 coronavirus infection and spread

In vitro testing of combined hydroxychloroquine and 700 azithromycin on SARS-CoV-2 shows synergistic effect

In vitro activity of lopinavir/ritonavir and 702 hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations 703 achievable by usual doses

Antimalarial drugs inhibit the replication of 705 SARS-CoV-2: An in vitro evaluation

Hydroxychloroquine use against SARS-CoV-2 707 infection in non-human primates

Quinine Inhibits Infection of Human Cell Lines with 709 SARS-CoV-2

The 711 pharmacokinetic and pharmacodynamic properties of hydroxychloroquine and dose selection 712 for COVID-19: putting the cart before the horse

Chloroquine and hydroxychloroquine 714 as available weapons to fight COVID-19

In Vitro Antiviral Activity and Projection of Optimized Dosing 716 Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome 717 Coronavirus 2 (SARS-CoV-2)

COVID-19 prevention 719 and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical 720 pharmacology

Antiviral activity of chloroquine against human coronavirus 722 OC43 infection in newborn mice

Favipiravir at high doses has potent antiviral 724 activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity

Chloroquine is effective against influenza A virus in vitro but not 727 in vivo. Influenza and Other Respiratory Viruses

Expert consensus on chloroquine phosphate for the treatment 729 of novel coronavirus pneumonia

Coronavirus Disease 2019, and 731 QT Prolongation

FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the 733 hospital setting or a clinical trial due to risk of heart rhythm problems

National Institute of Health. Chloroquine or Hydroxychloroquine With or Without 741 Azithromycin 2020

Concordance between the results 752 of randomized and non-randomized interventional clinical trials assessing the efficacy of drugs 753 for COVID-19: a cross-sectional study

Hydroxychloroquine in the treatment of outpatients with mildly 755 symptomatic COVID-19: a multi-center observational study

Hydroxychloroquine in Nonhospitalized Adults 757 With Early COVID-19

Randomized double-blinded placebo-controlled 759 trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe

Assessing the efficacy and safety of 762 hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial. 763 CMAJ Open

Effect of Early Treatment With 765 Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients 766 With COVID-19. The TOGETHER Randomized Clinical Trial

Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 769 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial 770 evaluating viral clearance

A Randomized Trial of Hydroxychloroquine 772 as Postexposure Prophylaxis for Covid-19

Hydroxychloroquine for the Prevention of Covid-19 -Searching for Evidence

A Cluster-Randomized Trial of 776 Hydroxychloroquine for Prevention of Covid-19

Hydroxychloroquine as Postexposure 778 Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A 779 Randomized Trial

Efficacy and Safety of Hydroxychloroquine vs 781 Placebo for Pre-Exposure SARS-CoV-2 Prophylaxis Among Health Care Workers

Hydroxychloroquine as pre-exposure 784 prophylaxis for coronavirus disease 2019 (COVID-19) in healthcare workers: a randomized 785 trial

Effect of Hydroxychloroquine pre-exposure on infection 787 with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study

Effect of pre-exposure use of hydroxychloroquine 790 on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis 791 or systemic lupus erythematosus using the OpenSAFELY platform

Safety of Hydroxychloroquine Among 794 Outpatient Clinical Trial Participants for COVID-19

Positive impact of oral hydroxychloroquine and 797 povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. Int 798

Post-exposure prophylaxis with hydroxychloroquine for 800 the prevention of COVID-19, a myth or a reality? The PEP-CQ Study

An orally bioavailable broad-spectrum antiviral inhibits 803 SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci 804 Transl Med

Systematic review and meta-analysis of 806 randomized trials of hydroxychloroquine for the prevention of COVID-19

Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized 809 Clinical Trials During Pandemics

Transparent Reporting of Systematic Reviews and meta-analyses

The Cochrane Collaboration's tool for assessing 813 risk of biasin randomized trials

Diarrhea was numerically higher with HC/AZ but QTc prolongation and SAEs were numerically higher with Placebo.